Document is current
Any future updates will be listed below
-
Authors
Boissière-Michot, Florence
Gudin-De-Vallerin, Amélie
Thézenas, Simon
Roca, Lise
Lopez-Crapez, Evelyne
Guiu, Séverine
Bobrie, Angelique
Jacot, William
Maran-Gonzalez, Aurélie
- License Information
-
More Information
Article History
Received: 21 July 2025
Revised: 14 January 2026
Accepted: 20 January 2026
First Online: 4 February 2026
Declarations
:
: All procedures implemented in this study complied with the ethical standards of the institutional and national research committees and the Declaration of Helsinki. Retrospective human samples were collected and managed by a Biological Resources Center declared (DC-033-00059) and approved (AC-2008-700) by the competent authorities. All patients included in the study were fully anonymized. This work was supported and approved by the Montpellier Cancer Institute Val d’Aurelle, Montpellier, France (ICM-CORT-2024-28).
: Séverine Guiu declares the following conflicts of interest: boards/oral presentation: AstraZeneca; travel: Novartis, Pfizer; financial support to research projects (institutional grants): Pfizer, Lilly, AstraZeneca. William Jacot reports grants, personal fees, and non-financial support from AstraZeneca, grants and personal fees from Daiichi Sankyo, personal fees and non-financial support from Eisai, personal fees and non-financial support from Novartis, personal fees and non-financial support from Roche, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Eli Lilly, personal fees from MSD, personal fees from BMS, personal fees and non-financial support from Chugai, personal fees from Seagen, and personal fees and non-financial support from Gilead outside the submitted work. All the other authors did not receive support from any organization relevant to the content of this article.
